Biotricity, Inc. (BTCY)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Biotricity, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Biotricity, Inc. (BTCY) has returned -21.32% so far this year and -30.58% over the past 12 months. Over the last ten years, BTCY has returned -33.92% per year, falling short of the S&P 500 Index benchmark, which averaged 12.16% annually.

Based on dividend-adjusted daily data since Feb 18, 2016, BTCY's average daily return is +0.15%, while the average monthly return is +1.38%. At this rate, your investment would double in approximately 4.2 years.

Historically, 42% of months were positive and 58% were negative. The best month was Jan 2019 with a return of +166.7%, while the worst month was Dec 2022 at -56.9%. The longest winning streak lasted 7 consecutive months, and the longest losing streak was 7 months.

On a daily basis, BTCY closed higher 40% of trading days. The best single day was Jun 14, 2016 with a return of +96.1%, while the worst single day was Jun 13, 2016 at -62.0%.

Biotricity, Inc. has an annualized alpha of 36.60%, beta of 0.44, and R² of 0.00 versus S&P 500 Index. Calculated based on daily prices since February 19, 2016.

• This stock participated in 182.11% of S&P 500 Index downside but only -14.45% of its upside — more exposed to losses than it benefited from rallies.
• Beta of 0.44 may look defensive, but with R² of 0.00 this stock is largely uncorrelated with S&P 500 Index — low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R² of 0.00 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

BTCY ranks 31 for risk / return — below 31% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.

The table below present risk-adjusted performance metrics for Biotricity, Inc. (BTCY) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Biotricity, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Biotricity, Inc. was 99.67%, occurring on Oct 1, 2024. The portfolio has not yet recovered.

The current Biotricity, Inc. drawdown is 99.61%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Biotricity, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Biotricity, Inc. is priced in the market compared to other companies in the Medical Devices industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.